Business
REGENXBIO Reports Second Quarter 2020 Financial Results and Operational Highlights
-- RGX-314 subretinal delivery pivotal program for wet AMD to initiate by end of 2020; positive interim update from Cohorts 4 and 5 at one year in Phase I/IIa
About this update from Regenxbio Inc.
[{"type":"text","content":"-- RGX-314 subretinal delivery pivotal program for wet AMD to initiate by end of 2020; positive interim update from Cohorts 4 and 5 at one year in Phase I/IIa trial recently announced\n -- Phase II trial for RGX-314 for wet AMD using suprachoroidal delivery expected to begin enrollment in Q3 2020\n -- Phase II trial for RGX-314 for diabetic retinopathy on track to initiate in second half of 2020\n -- Recently reported progress in RGX-111 and RGX-121 programs; additional program updates are expected later this year\n -- Company announces new program, RGX-381, for the treatment of ocular manifestations of CLN2 disease\n -- Company announces discontinuation of internal clinical development of RGX-501 for HoFH\n -- $339 million in cash, cash equivalents and marketable securities as of June 30, 2020\n -- Q2 earnings conference call Thursday, August 6 at 4:30 p.m. ET\n\n\nROCKVILLE, Md., Aug. 6, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced financial results for the quarter ended June 30, 2020, and recent operational highlights.\n\"Now halfway through 2020 and with the backdrop of the challenging COVID-19 pandemic, I am pleased that we have made significant progress in our gene therapy programs and continue to make important decisions with respect to our pipeline and plans. We expect to initiate the RGX-314 wet AMD pivotal program later this year based on the latest data from our RGX-314 Phase I/IIa trial, which has demonstrated durable treatment effect, with stable to improved visual acuity and retinal thickness. We also look forward to dosing patients in our RGX-314 trials using the suprachoroidal delivery approach for the treatment of wet AMD and diabetic retinopathy later this year,\" said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. \"Our team has also been hard at work moving our CNS-focused gene therapy programs forward. We have completed dosing of patients in the second cohort of our Phase I/II study of RGX-121 for the treatment of MPS II, which includes one patient dosed in Brazil at our first ex-U.S. gene therapy site. We look forward to providing additional updates for this program, as well as our RGX-111 progr...